|drug514||Blood for pharmacokinetic samples Wiki||1.00|
|drug513||Blood for anti-drug antibody (ADA) Wiki||1.00|
|drug2164||Nasopharyngeal, oropharyngeal, or saliva swab Wiki||1.00|
|D000066553||Problem Behavior NIH||0.38|
|D001523||Mental Disorders NIH||0.20|
|D040921||Stress Disorders, Traumatic NIH||0.19|
There is one clinical trial.
Primary objective is to evaluate the feasibility of delivering an online early Eye Movement Desensitisation Reprocessing (EMDR) Recent Traumatic Events Protocol (R-TEP) to patients who have survived Covid-19 related critical illness, within the context of a randomised controlled trial (RCT). This will inform the design of a future RCT investigating the effectiveness of EMDR R-TEP in reducing psychological symptoms, for adult survivors of intensive care.
Description: Feasibility will be determined by the following measures: Able to recruit >30% of eligible patients approached Complete early EMDR intervention programme in 75% or more of trial participants randomised to intervention. Protocol adherence Assignment of causality of serious events will be assessed by the chief investigator. Events attributable to trial procedures will be reviewed by trial management board, study sponsor and the research ethics committee, in order to determine ongoing feasibility. Outcome measures completed in 75% or more of trial participantsMeasure: Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints Time: 12 months
Description: The PTSD Checklist-Civilian Version (PCL-C) is a validated, standardised self-reporting questionnaire for PTSD comprising of 17 items that correspond to key PTSD symptomsMeasure: Post-Traumatic stress disorder Time: 6 months post-hospital discharge
Description: Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-reported measure with 7-items relating to symptoms of anxiety and 7-items relating to depressionMeasure: Anxiety and depression Time: 6 months
Description: Montreal Cognitive Assessment (MoCA) is a validated tool, used to detect cogntive impairmentMeasure: Cognitive function Time: 6 months post-hospital discharge
Description: EQ5D -5L comprises five quality-of-life dimensions; mobility, self-care, usual activities, pain/discomfort andanxiety/depression.Measure: Health Related Quality of Life Time: 6 months post-hospital discharge
Description: WHODAS 2.0 is a generic assessment tool that produces standarised disability levels and profilesMeasure: Health and disability Time: 6 months post-hospital discharge
Description: Wrist worn physical activity monitoringMeasure: Physical activity Time: 6 months post-hospital discharge
Description: Patient generated subjective global assessmentMeasure: Nutritional status Time: 6 months post-hospital discharge
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports